

REMARKS

Claims 1–8 are pending. Claims 1 and 8 are currently amended.

The Applicant respectfully requests reconsideration and withdrawal of the rejection of claims 1 and 6–8 under 35 U.S.C. 112, first and second paragraphs, because (1) the use of the term “imino” in claim 1 has been clarified (*i.e.*, both bonds are on the N); (2) the N at the 3 and 9 position are not claimed to be methylated or ethylated; and (3) the claimed method of claim 8 is for treating *inter alia* “allograft transplantation osteoporosis” and “rheumatoid arthritis”.

Respectfully submitted,

/THOMAS BLANKINSHIP/

Thomas Blankinship
Reg. No. 39,909

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 791-6615

December 14, 2005